Full-Time

Insights Manager

GoodRx

GoodRx

1,001-5,000 employees

Prescription price comparison and coupons

Compensation Overview

$136k - $216k/yr

+ Bonus + Equity Grants

Remote in USA

Remote

Bachelor's, Master's

Category
Data & Analytics (1)
Required Skills
Redshift
SQL
Tableau
Looker
Data Analysis
PowerPoint/Keynote/Slides

Get referred to GoodRx

See people who can refer or advise you

Requirements
  • 8+ years of professional experience in consumer/user experience research and a Bachelor’s degree or 6 years of experience and a Masters degree.
  • Extensive experience with survey design, sampling, weighting and basic statistical analysis is required.
  • Expertise in Alchemer or Qualtrics is required.
  • Experience with Dscout, UserInterviews, or similar qual tool.
  • Presentation building skills (PowerPoint, Google Slides) and a good eye for concise data visualization.
  • Exceptional communication skills and ability to synthesize findings for both technical and non-technical audiences
  • Basic knowledge of SQL, Redshift, and Tableau is preferred but not required.
  • Experience in healthcare is preferred but not required.
  • Experience in AI research tools is preferred but not required.
Responsibilities
  • Product and Audience Research: Designing and executing complex research studies that inform the development and continued optimization of GoodRx’s subscription services and Core product offerings.
  • Measurement: Managing longitudinal CSAT/NPS and other KPI studies for ongoing internal and external reporting across all GoodRx product offerings.
  • BI/Analytics Support: Delivering analytics support to the Insights team, as needed, working in Redshift, Tableau and Lookr to pull customer data and develop relevant dashboards.
  • End-to-end delivery of iterative research studies, which will require: Leveraging multiple primary and secondary quantitative data sets to answer key questions, ensuring a holistic analysis of problems and potential insights.
  • Managing the execution of research studies, including sampling, data collection, cleaning and weighting to ensure the highest level of data quality;
  • Data analysis, including cross tabulation and dashboard creation to generate meaningful findings; and,
  • Report development, specifically creating meaningful but digestible reports that clearly communicate findings to non-research audiences (e.g. senior leadership, sales, product, design).
  • All GoodRx employees are responsible for reviewing and complying with all Company safety and security policies and procedures, being vigilant and observant of potential security threats (including phishing attempts) and proactively communicating with the Security Team to raise any concerns.
Desired Qualifications
  • Experience in healthcare is preferred but not required.
  • Experience in AI research tools is preferred but not required.
  • Basic knowledge of SQL, Redshift, and Tableau is preferred but not required.

GoodRx provides price comparisons, coupons, and discounts for prescription medications through its website and mobile app. It partners with pharmacies to offer savings at the point of sale, earning referral fees. It also offers GoodRx Gold subscription with deeper discounts and earns revenue from ads and partnerships. The goal is to save people money on prescriptions and improve access to affordable medicines.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Santa Monica, California

Founded

2005

Get referred to GoodRx

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 subscription revenue rose 39% to $28.5 million, driven by Companion.
  • Pharma Direct revenue jumped 76% year over year, boosted by GLP-1 programs.
  • GoodRx raised 2026 revenue guidance to $790-$805 million after August 5 results.

What critics are saying

  • Legacy prescription transactions fell 26% in Q2 2026 as monthly active consumers dropped.
  • FTC's health-data case remains a standing warning after GoodRx's 2023 $1.5 million settlement.
  • If GLP-1 manufacturers bypass GoodRx, Pharma Direct growth collapses and margins compress.

What makes GoodRx unique

  • GoodRx's Pharma Direct sold $61.6 million in Q2 2026, linking manufacturers to consumers.
  • GoodRx Companion bundles coupons, telehealth, dental, vision, and labs into one subscription.
  • GoodRx reaches 70,000 pharmacies, giving nationwide cash-pay access other apps cannot match.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical, dental, and vision insurance

401(k) with a company match

ESPP

Unlimited vacation

"Take care of yourself" days

11 paid holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Yahoo Finance
Aug 14th, 2026
GoodRx reports Q2 revenues of $200M, delivers slowest growth among healthcare tech peers

GoodRx reported second-quarter revenues of $200.4 million, down 1.3% year-on-year but exceeding analyst expectations by 3.5%. The prescription drug price comparison platform delivered the slowest revenue growth among seven healthcare technology stocks tracked in the analysis. Despite the modest performance, GoodRx provided strong forward guidance. Its full-year revenue and EBITDA forecasts both topped analyst expectations. The stock has responded positively, rising 14.1% since the earnings announcement and currently trading at $3.73. The company, founded in 2011, helps consumers find lower prescription medication prices through comparison tools and discount codes. The healthcare technology sector as a group reported strong results, with revenues beating consensus estimates by 3.7% and next quarter guidance exceeding expectations by 2.8%. Share prices across the sector have risen 6.8% on average following the latest earnings.

MarketBeat
Aug 11th, 2026
GoodRx (NASDAQ:GDRX) stock price expected to rise, Citigroup Analyst says.

GoodRx (NASDAQ:GDRX) stock price expected to rise, Citigroup Analyst says. August 11, 2026 Key points. * Citigroup raised GoodRx's price target from $4.00 to $5.00 and maintained a "buy" rating, implying 31.41% upside from the previous close. * Analyst sentiment remains mixed: GoodRx has an average "Hold" rating and a consensus price target of $4.16, while Wells Fargo and TD Cowen also raised their targets to $5.00. * GoodRx reported quarterly EPS of $0.08, in line with estimates, and revenue of $200.41 million, above expectations but down 1.3% year over year. The stock recently traded at $3.81, while institutional investors own 63.77% of shares. * MarketBeat previews the top five stocks to own by September 1st. GoodRx (NASDAQ:GDRX - Get Free Report) had its price target increased by analysts at Citigroup from $4.00 to $5.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Citigroup's price objective indicates a potential upside of 31.41% from the company's previous close. A number of other analysts also recently weighed in on the company. The Goldman Sachs Group reiterated a "neutral" rating and set a $4.00 price target on shares of GoodRx in a report on Friday. Wells Fargo & Company upped their target price on GoodRx from $3.50 to $5.00 and gave the company an "overweight" rating in a research report on Friday. TD Cowen lifted their target price on GoodRx from $4.00 to $5.00 and gave the stock a "buy" rating in a report on Tuesday. Leerink Partners set a $5.00 price target on GoodRx in a report on Thursday. Finally, Weiss Ratings upgraded shares of GoodRx from a "sell (d)" rating to a "sell (d+)" rating in a research note on Friday. Four investment analysts have rated the stock with a Buy rating, six have given a Hold rating and three have issued a Sell rating to the company's stock. According to data from MarketBeat, GoodRx currently has an average rating of "Hold" and an average price target of $4.16. GoodRx price performance. GDRX stock traded up $0.14 during midday trading on Tuesday, reaching $3.81. 1,750,660 shares of the stock were exchanged, compared to its average volume of 2,112,026. GoodRx has a 52 week low of $1.77 and a 52 week high of $5.81. The company has a fifty day moving average price of $2.96 and a 200 day moving average price of $2.55. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.38 and a quick ratio of 1.38. The stock has a market capitalization of $1.30 billion, a PE ratio of 95.15, a P/E/G ratio of 1.70 and a beta of 1.60. GoodRx (NASDAQ:GDRX - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.08 EPS for the quarter, meeting the consensus estimate of $0.08. GoodRx had a return on equity of 7.22% and a net margin of 2.07%.The firm had revenue of $200.41 million during the quarter, compared to the consensus estimate of $193.23 million. During the same period last year, the company earned $0.09 earnings per share. The business's quarterly revenue was down 1.3% on a year-over-year basis. As a group, analysts expect that GoodRx will post 0.17 EPS for the current fiscal year. Institutional inflows and outflows. A number of large investors have recently made changes to their positions in the business. Prescott Group Capital Management L.L.C. bought a new stake in shares of GoodRx during the fourth quarter worth about $4,812,000. Technology Crossover Management X Ltd. acquired a new position in GoodRx during the 2nd quarter valued at about $4,762,000. Northwestern Mutual Wealth Management Co. boosted its stake in GoodRx by 10,242.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,502,666 shares of the company's stock valued at $4,072,000 after purchasing an additional 1,488,137 shares during the last quarter. AQR Capital Management LLC increased its holdings in GoodRx by 188.0% during the 4th quarter. AQR Capital Management LLC now owns 1,158,546 shares of the company's stock worth $3,140,000 after purchasing an additional 756,209 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in GoodRx by 7.3% during the 3rd quarter. Vanguard Group Inc. now owns 9,207,340 shares of the company's stock worth $38,947,000 after purchasing an additional 624,182 shares in the last quarter. 63.77% of the stock is owned by institutional investors. GoodRx company profile. GoodRx Holdings, Inc NASDAQ: GDRX operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications. In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider GoodRx, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list. While GoodRx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Yahoo Finance
Aug 10th, 2026
GoodRx subscription revenue jumps 39% as platform expands beyond prescription savings

GoodRx is expanding beyond prescription savings as subscription revenue climbed 39% year over year. CEO Wendy Barnes told Yahoo Finance the company expects to return to top-line growth this year, earlier than anticipated, though at low single-digit rates. The platform maintains around 280 million site visits but is seeing shifts in user behaviour. There's been considerable increase in users seeking GLP-1 coverage as many employers don't cover these medications. Barnes said users are looking for longer-term value and the ability to fill their entire medicine cabinet rather than using multiple point solutions. Direct-to-pharma sales rose 76% year over year.

Yahoo Finance
Jul 17th, 2026
SEI Investments posts 27.9% operating margin as GoodRx and Hanover Insurance face growth headwinds

SEI Investments stands out as a profitable long-term investment opportunity, whilst GoodRx and The Hanover Insurance Group face headwinds, according to StockStory analysis. SEI Investments, which provides technology platforms and investment management solutions, boasts a 27.9% trailing 12-month GAAP operating margin. Founded in 1968, the company serves financial institutions, wealth managers, and investors. Meanwhile, GoodRx struggles with flat sales over two years and negative returns on capital, despite its 9.9% operating margin. The prescription drug price comparison platform has a modest revenue base of $787.9 million. The Hanover Insurance Group, with a 14.8% operating margin, faces challenges including below-standard revenue growth of 4.9% annually over two years and lacklustre policy growth of 4.2% yearly, underperforming typical financial institutions.

The News-Press
Jun 2nd, 2026
New 'GoodRx Companion' subscription targets rising costs.

New 'GoodRx Companion' subscription targets rising costs. Fort Myers News-Press & Naples Daily News June 2, 2026, 5:07 a.m. ET * GoodRx has launched a new subscription program called GoodRx Companion for $14.99 per month. * The program offers savings on generic medications, online care visits, lab work, and dental and vision care. * This new service is a response to rising healthcare costs and inflation affecting American consumers. GoodRx, an online resource for discounted medications, has launched a membership program that ties in health-care services for consumers. There also is savings for dental and vision care, according to the Santa Monica, Calif-based online platform. The company says it helps nearly 25 million American consumers annually with discounts. "GoodRx Companion is an important step in our evolution toward building a broader subscription model built for the way consumers are navigating healthcare today," Wendy Barnes, president and chief executive officer of GoodRx, said in a news release. The offering comes as Americans see their budgets squeezed by inflation, and higher costs for health care. Many Americans lost what was called "enhanced" premium assistance at the end of 2025 for health insurance through Affordable Care Act. Congress did not reinstate the assistance in 2025 that became a primary cause for a 43-day government shutdown, the longest ever from Oct. 1 to mid November. The enhanced premium assistance were enacted in 2021 during COVID-19 pandemic disruptions. For many Americans to afford higher premiums this year for their ACA plans or even with employer-sponsored coverage, they've opted for higher deductibles and other out-of-pocket cost sharing. Can GoodRx Companion help you? GoodRx says its new service is an option to address health care affordability issues, Barnes said. "As coverage becomes more complex and out-of-pocket costs continue to rise, people are looking for trusted solutions that give them greater control and clearer value," she said. The company says it has tapped its pricing capabilities, retail pharmacy relationships, and consumer experience that it has built over more than a decade to launch the subscription service to make health care more affordable and predictable, according to the company. Since 2011, GoodRx says it has helped Americans save more than $100 billion on the cost of their medications. At the same time, the digital platform has been under scrutiny. In 2023, the Federal Trade Commission said GoodRx shared information about users' health conditions and prescription drugs with digital advertisers like Facebook and Google without permission and contrary to what it told users in its privacy policy. GoodRx settled with the federal agency that same year, agreeing to pay a $1.5 million civil penalty. It is prohibited from sharing users' health data with applicable third parties for advertising purposes. The company said it admitted no wrongdoing and said the FTC focused on an old issue that was proactively addressed three years before the government inquiry began. What do you get with GoodRx Companion? * Prescription savings: More than 200 common generic medications for free, with hundreds more for less than $10, available at nearly every pharmacy nationwide * Online care: $19 telehealth visits on GoodRx Care for common needs such as UTIs, skin care, flu, and other routine conditions * Dental care: Savings on cleanings, exams, X-rays, crowns, and other dental services * Vision care: Savings on eye exams, glasses, contact lenses, and laser eye surgery * Lab and imaging services: Significant savings on common lab and imaging services such as MRIs, CT scans, ultrasounds, comprehensive wellness labs, and hormone panels Do you have an opinion about this topic? Write a letter to the editor and send it [email protected] and/or [email protected]. Keep it to 250 words or fewer and include your contact info. Have more to say: Send a guest column of no more than 600 words. Liz Freeman is a health care reporter. Reach her by emailing [email protected] Please support local community journalism and stay informed about Southwest Florida news by subscribing to The News-Press and Naples Daily News; download the free News-Press or Naples Daily News app, and sign up for daily briefing email newsletter, food & dining and growth & development newsletters here and here.